尿酸脏病是二次的一般化性性发作
Amanda Simon1, Dan Nguyen2, Blake Newman1
1Department of Neurology, University of Utah, Salt Lake City, UT.
The neurologist
|October 15, 2023
概括
尿酸脏病引起的急性损伤是泛起的强力克隆性发作的未被认可的并发症. 早期脏病学咨询和拉斯布里卡斯可以预防严重的脏损伤并减少透析的需要.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 神经学 神经学
- 关键护理医学 关键护理医学
背景情况:
- 总化的强力克隆性发作可能导致急性损伤 (AKI),通常是由于狂犬病.
- 尿酸脏病是AKI在患者中未被认可的原因.
- 发表的尿酸脏病发作后的病例报告很少.
研究的目的:
- 突出尿酸脏病作为AKI的原因,在经历了泛性强力克隆性发作的患者中.
- 强调早期识别和管理高尿路血症在这个患者群体中的重要性.
主要方法:
- 病例系列描述了三名男性患者的病例,他们患有泛性强度-克隆性发作和随后的AKI.
- 分析了包括血清尿酸水平在内的实验室数据.
- 记录了诸如血液透析和拉斯布里卡斯等治疗干预措施.
主要成果:
- 这三名患者的血清尿酸水平显著升高 (19.520.7 mg/dL),功能恶化.
- 两名患者需要进行血液透析.
- 一名接受拉斯布里卡斯治疗的患者表现出功能恢复.
结论:
- 尿酸脏病是一种罕见但严重的并发症,常常被忽视的通用性强力克隆性发作.
- 及时识别和干预,包括拉斯布里卡斯,可以减轻置换治疗的需要.
- 建议在患有发作和功能下降的患者进行早期脏病咨询,以考虑尿酸脏病管理.
相关概念视频
Seizures: Classification
378
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
378
Antiepileptic Drugs: GABAergic Pathway Potentiators
426
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
426
Antiepileptic Drugs: Potassium Channel Activators
192
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
192
Antiepileptic Drugs: Glutamate Antagonists
387
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
387
Arteries of the Lower Limbs
194
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
194
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
318
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
318


